Kakodkar et al. demonstrated that BRAF inhibition using Sorafenib inhibited NB growth in vivo, attenuated ERK signaling, and arrested the cell cycle at the G1/G0 stage [123]. The gene discussed is BRAF; the disease is neuroblastoma.